Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 3/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21577923 | 0.98 | HSD17B10 (0.55) | MAPTRXFP1HSD17B10RXRANR1H2 | |
| SCHEMBL1744284 | 0.89 | LMNA (0.54) | HSD17B10RXRANR1H2NR1H3S1PR1 | |
| SCHEMBL3790673 | 0.88 | NR1H4 (0.51) | HSD17B10RXRANR1H2NR1H3NR1H4 | |
| SCHEMBL4183681 | 0.86 | CYP4A11 (0.52) | MAPTHSD17B10RXRANR1H2NR1H3 | |
| SCHEMBL1743875 | 0.86 | CYP4A11 (0.52) | MAPTHSD17B10RXRANR1H2NR1H3 | |
| SCHEMBL8568072 | 0.85 | CYP4A11 (0.67) | MAPTNR1H2CYP4A11CYP4F2FAAH | |
| SCHEMBL20046685 | 0.85 | CYP4A11 (0.67) | MAPTNR1H2CYP4A11CYP4F2FAAH | |
| SCHEMBL8997287 | 0.84 | CYP4A11 (0.54) | RXRANR1H2NR1H3CYP4A11CYP4F2 | |
| SCHEMBL15908887 | 0.84 | MAPT (0.56) | MAPTRXFP1HSD17B10RXRANR1H2 | |
| SCHEMBL30873953 | 0.84 | RXRA (0.56) | HSD17B10RXRANR1H2NR1H3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2386572-B1 | Insulin derivative | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| EP-2015770-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2012-09-26 | — | — | EP | disclosed |
| EP-2386572-A1 | Insulin derivative | Novo Nordisk A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-8039101-B2 | Radio-opaque dental prosthetic member | Societe de Recherches Techniques Dentaires-R.T.D. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | MAPT 3865/4885RXFP1 442/4885HSD17B10 204/4885 |
| US-20090105121-A1 | Insulin Derivative | INSR, IAPP, GPR119 | MAPT 3955/4885RXFP1 351/4885HSD17B10 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.